Michael A Lane1, Angelique Zeringue2, Jay R McDonald2. 1. Washington University, St. Louis, Mo. Electronic address: mlane@dom.wustl.edu. 2. Washington University, St. Louis, Mo; St. Louis Veterans Affairs Medical Center, St. Louis, Mo.
Abstract
BACKGROUND: Antibiotics may interact with warfarin, increasing the risk for significant bleeding events. METHODS: This is a retrospective cohort study of veterans who were prescribed warfarin for 30 days without interruption through the US Department of Veterans Affairs between October 1, 2002 and September 1, 2008. Antibiotics considered to be high risk for interaction with warfarin include: trimethoprim/sulfamethoxazole (TMP/SMX), ciprofloxacin, levofloxacin, metronidazole, fluconazole, azithromycin, and clarithromycin. Low-risk antibiotics include clindamycin and cephalexin. Risk of bleeding event within 30 days of antibiotic exposure was measured using Cox proportional hazards regression, adjusted for demographic characteristics, comorbid conditions, and receipt of other medications interacting with warfarin. RESULTS: A total of 22,272 patients met inclusion criteria, with 14,078 and 8194 receiving high- and low-risk antibiotics, respectively. There were 93 and 36 bleeding events in the high- and low-risk groups, respectively. Receipt of a high-risk antibiotic (hazard ratio [HR] 1.48; 95% confidence interval [CI], 1.00-2.19) and azithromycin (HR 1.93; 95% CI, 1.13-3.30) were associated with increased risk of bleeding as a primary diagnosis. TMP/SMX (HR 2.09; 95% CI, 1.45-3.02), ciprofloxacin (HR 1.87; 95% CI, 1.42-2.50), levofloxacin (HR 1.77; 95% CI, 1.22-2.50), azithromycin (HR 1.64; 95% CI, 1.16-2.33), and clarithromycin (HR 2.40; 95% CI, 1.16-4.94) were associated with serious bleeding as a primary or secondary diagnosis. International normalized ratio (INR) alterations were common; 9.7% of patients prescribed fluconazole had INR value >6. Patients who had INR performed within 3-14 days of co-prescription were at a decreased risk of serious bleeding (HR 0.61; 95% CI, 0.42-0.88). CONCLUSIONS: Warfarin users who are prescribed high-risk antibiotics are at higher risk for serious bleeding events. Early INR evaluation may mitigate this risk.
BACKGROUND: Antibiotics may interact with warfarin, increasing the risk for significant bleeding events. METHODS: This is a retrospective cohort study of veterans who were prescribed warfarin for 30 days without interruption through the US Department of Veterans Affairs between October 1, 2002 and September 1, 2008. Antibiotics considered to be high risk for interaction with warfarin include: trimethoprim/sulfamethoxazole (TMP/SMX), ciprofloxacin, levofloxacin, metronidazole, fluconazole, azithromycin, and clarithromycin. Low-risk antibiotics include clindamycin and cephalexin. Risk of bleeding event within 30 days of antibiotic exposure was measured using Cox proportional hazards regression, adjusted for demographic characteristics, comorbid conditions, and receipt of other medications interacting with warfarin. RESULTS: A total of 22,272 patients met inclusion criteria, with 14,078 and 8194 receiving high- and low-risk antibiotics, respectively. There were 93 and 36 bleeding events in the high- and low-risk groups, respectively. Receipt of a high-risk antibiotic (hazard ratio [HR] 1.48; 95% confidence interval [CI], 1.00-2.19) and azithromycin (HR 1.93; 95% CI, 1.13-3.30) were associated with increased risk of bleeding as a primary diagnosis. TMP/SMX (HR 2.09; 95% CI, 1.45-3.02), ciprofloxacin (HR 1.87; 95% CI, 1.42-2.50), levofloxacin (HR 1.77; 95% CI, 1.22-2.50), azithromycin (HR 1.64; 95% CI, 1.16-2.33), and clarithromycin (HR 2.40; 95% CI, 1.16-4.94) were associated with serious bleeding as a primary or secondary diagnosis. International normalized ratio (INR) alterations were common; 9.7% of patients prescribed fluconazole had INR value >6. Patients who had INR performed within 3-14 days of co-prescription were at a decreased risk of serious bleeding (HR 0.61; 95% CI, 0.42-0.88). CONCLUSIONS:Warfarin users who are prescribed high-risk antibiotics are at higher risk for serious bleeding events. Early INR evaluation may mitigate this risk.
Authors: Jacques Baillargeon; Holly M Holmes; Yu-Li Lin; Mukaila A Raji; Gulshan Sharma; Yong-Fang Kuo Journal: Am J Med Date: 2012-02 Impact factor: 4.965
Authors: Nathan P Clark; Thomas Delate; Catherine S Riggs; Daniel M Witt; Elaine M Hylek; David A Garcia; Walter Ageno; Francesco Dentali; Mark A Crowther Journal: JAMA Intern Med Date: 2014-03 Impact factor: 21.873
Authors: Loes E Visser; Fernie J A Penning-van Bees; A A Harrie Kasbergen; Peter A G M De Smet; Arnold G Vulto; Albert Hofman; Bruno H Ch Stricker Journal: Thromb Haemost Date: 2002-11 Impact factor: 5.249
Authors: Andrew Cunningham; C Michael Stein; Cecilia P Chung; James R Daugherty; Walter E Smalley; Wayne A Ray Journal: Pharmacoepidemiol Drug Saf Date: 2011-03-08 Impact factor: 2.890
Authors: Daniel E Singer; Yuchiao Chang; Margaret C Fang; Leila H Borowsky; Niela K Pomernacki; Natalia Udaltsova; Alan S Go Journal: Circ Cardiovasc Qual Outcomes Date: 2009-06-09
Authors: Anna Powers; Erin B Loesch; Anthony Weiland; Nicole Fioravanti; David Lucius Journal: J Thromb Thrombolysis Date: 2017-07 Impact factor: 2.300
Authors: Adam Wright; Skye Aaron; Diane L Seger; Lipika Samal; Gordon D Schiff; David W Bates Journal: J Gen Intern Med Date: 2018-05-15 Impact factor: 5.128